1-14 of 14
carcinoma, transitional cell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, MD PhD, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, MD PhD, Simon Rule, Javier Munoz, MD, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood
Blood (2019) 134 (Supplement_1): 5320.
https://doi.org/10.1182/blood-2019-124102
Published: 2019
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2874.
https://doi.org/10.1182/blood-2019-123368
Published: 2019
Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2917.
https://doi.org/10.1182/blood-2019-123664
Published: 2019
Journal Articles

Immune Sculpting of Clonal Hematopoiesis in Advanced and Metastatic Solid Tumors

Eti Sinha, Bhavneet Binder, Olivier Elemento, PhD, Duane C. Hassane, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3721.
https://doi.org/10.1182/blood-2019-132222
Published: 2019
Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl
Journal: Blood
Blood (2019) 134 (Supplement_1): 3939.
https://doi.org/10.1182/blood-2019-125153
Published: 2019
Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1907.
https://doi.org/10.1182/blood-2019-123652
Published: 2019
Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman
Journal: Blood
Blood (2019) 134 (Supplement_1): 829.
https://doi.org/10.1182/blood-2019-122896
Published: 2019
Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 3236.
https://doi.org/10.1182/blood-2019-125963
Published: 2019
Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 690.
https://doi.org/10.1182/blood-2018-99-110388
Published: 2018
Journal Articles

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, MD, Luciano J Costa, MD PhD, Faith E. Davies, MD, Natalia Neparidze, MD, Ravi Vij, Yuning Feng, Anastasia Teterina, Elisabeth Wassner Fritsch, Michael Wenger, Jonathan L Kaufman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 597.
https://doi.org/10.1182/blood-2018-99-114960
Published: 2018
Journal Articles

Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies

Chakra P Chaulagain, MD, FACP, Esha Kaul, MD, Monika Pilichowska, MD, Andreas K. Klein, MD, Kellie Sprague, MD, Kenneth B. Miller, MD
Journal: Blood
Blood (2013) 122 (21): 5496.
https://doi.org/10.1182/blood.V122.21.5496.5496
Published: 2013
Journal Articles

Splenic Marginal Zone Lymphoma (SMZL): Clinical Course after Splenectomy. A Single Institution Experience

Susanna S Gaykazyan, Nalini Janakiraman, MD, Philip Kuriakose, Koichi Maeda, Tareq Hammour
Journal: Blood
Blood (2008) 112 (11): 3993.
https://doi.org/10.1182/blood.V112.11.3993.3993
Published: 2008
Journal Articles

Follicular Lymphoma of the GI Tract - Distinct Entity or Extranodal Manifestation of Nodal Disease?.

Sharmila Mehta, MD, Anita Kulharya, Andre Kallab, Fermina M. Mazzella
Journal: Blood
Blood (2005) 106 (11): 4703.
https://doi.org/10.1182/blood.V106.11.4703.4703
Published: 2005
Journal Articles

Tumor-Derived Lactic Acid Modulates Dendritic Cell Activation and Differentiation.

Marina Kreutz, PhD, Eva Gottfried, PhD, Leoni Kunz-Schughart, PhD, Sabine Hoves, PhD, Reinhard Andreesen, MD, Wolfgang Muller-Klieser, PhD, Andreas Mackensen, MD
Journal: Blood
Blood (2004) 104 (11): 4246.
https://doi.org/10.1182/blood.V104.11.4246.4246
Published: 2004